Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 106 publications
BEACON-HCC: Best evidence and north american consensus on treatment allocation for hepatocellular carcinoma.
Journal: Hepatology (Baltimore, Md.)
Published: July 23, 2026
Extended Follow-Up of Botensilimab Plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer Without Active Liver Metastases.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 01, 2026
Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors.
Journal: The New England journal of medicine
Published: February 25, 2026
Safety and efficacy of intratumoral MEDI1191, an IL-12 mRNA lipid nanoparticle, plus intravenous durvalumab in patients with advanced solid tumors: a first-in-human study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 07, 2026
A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasms.
Journal: British journal of cancer
Published: December 15, 2025
Outcomes of Patients With Solid Tumor Treated on Phase I Clinical Trials Within a Comprehensive Cancer Center's Private and Safety-Net Hospitals.
Journal: JCO oncology practice
Published: December 03, 2025
Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer.
Journal: Journal for immunotherapy of cancer
Published: November 23, 2025
A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular Carcinoma.
Journal: Liver cancer
Published: October 07, 2025
Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation study.
Journal: EBioMedicine
Published: July 03, 2025
Navigating second-line therapy after immunotherapy in advanced HCC☆.
Journal: JHEP reports : innovation in hepatology
Published: April 03, 2025
Isoform specific regulation of osteopontin by AKT2 in hepatocytes and livers.
Journal: Cellular signalling
Published: April 02, 2025
Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance).
Journal: ESMO open
Published: March 24, 2025
Last Updated: 09/26/2026